We won! 2026 Best Overall Patient Engagement Platform →

Videra Health · Life Sciences Overview

Behavioral evidence,
from trial to treatment.

Videra is a multimodal AI platform that runs from Phase 1 through commercial launch — and keeps working alongside you afterward. The same stack that powers your Phase 3 visit becomes a screener like TDScreen, surfacing the patients who need diagnosis so providers can actually treat them. One platform, trial to treatment, end-to-end.

Measurement · Quantifying the qualitative

One input, four powerful signals. The whole human.

From a single patient recording — a two-minute open-ended response, an in-clinic encounter, or a remote check-in on a phone — our models extract four parallel streams of behavioral evidence that survey instruments alone cannot reach.

Signal 1

Video

Facial expression, micro-movement, gaze, and motor cues extracted from short, validated clinical sessions.

Signal 2

Voice

Prosody, pace, sentiment, and affect — the vocal biomarkers that index depression, anxiety, and treatment response.

Signal 3

Language

Semantics, absolutist patterns, thematic shifts, and linguistic complexity — signal that long predates the clinical event.

Signal 4

Movement

Involuntary motion, posture shifts, and motor signs — the basis for TD, Parkinsonian, and movement-disorder endpoints.

100k+
Patients assessed across real-world deployments
3.5k+
Providers and site staff using Videra
300+
Sites and facilities running on Videra
50+
Conditions currently assessed

An example of how Videra works

Four clinical scores from a single, two-minute recording.

A patient completes one open-ended video response. Our multimodal AI extracts four parallel signal streams and routes them through validated condition-specific models — producing clinician-grade scores across depression, anxiety, trauma, and perinatal mental health from the same capture.

PHQ-9
0.88-0.90
AUC · Depression
GAD-7
0.90
AUC · Anxiety
PCL-5
0.85-0.90
AUC · PTSD
EPDS
0.89
AUC · Perinatal

AUC > 0.80 is considered highly accurate. Perfect model = 1.0.

The measure library

Two methods of measurement, and this is just the start.

Almost any validated paper-and-pencil instrument runs natively. The unique value is what our models extract from open-ended video responses — measures static surveys cannot produce.

Open-Ended Assessment

Extracted from open-ended video responses.

Validated outputs

PHQ-9 GAD-7 PCL-5 EPDS AIMS · TD MMSE

Behavioral signal

Suicidal language Sentiment Rate of speech Language complexity Absolutist language

Affect

Happiness Sadness Anger Fear Calm Surprise

In development

MADRS HAM-A HAM-D PANSS GRID-HAMD

Traditional Measures

Any validated instrument, administered natively. Multiple choice, sliders, branching logic.

Condition / diagnostic

PCL-5 ASRS-5 C-SSRS GAD-2/7 PHQ-2/9 YBOCS YMRS BAM PQ-B Bipolar Self-harm

Population health & outcomes

HRSN GSES ACE PACE GHQ-12 MSPSS PSC CHIP-R

Full instrument list available on request.

Where we fit

One platform, end-to-end across the drug lifecycle.

The same capture and AI stack that observes a Phase 3 visit runs a post-market screener two years later. Sponsors pick the lanes that matter most to them — the data, the models, and the patient experience carry through.

In Trials In Commercial

Phase 1-2

Early trial

Patient screening, eligibility, baseline behavioral capture.

Phase 3

Pivotal trial

Multi-site fidelity, digital endpoints, dosing-session oversight.

Phase 4

Post-market

ePRO, longitudinal monitoring, real-world evidence.

Launch

Commercial

Predictive screeners, patient identification, advocacy.

Growth

Adoption & access

Underdiagnosed populations, HEOR, market access.

Lifecycle

Ongoing RWE

Novel digital endpoints, med affairs insight, monitoring.

Collaboration

Capture. Analyze. Co-Develop. Pick the entry point.

Bring us a question and we'll capture the data. Bring us your data and we'll run it through our models. Or start from a hypothesis and we'll co-develop a novel endpoint with you, end-to-end.

Capture

Trial or study data capture

We bring the hardware, software, and AI to your site. Behavioral signal collected the same way at every visit, every site, every time.

Carts, web flows, and the secure pipeline you'd otherwise stitch together yourself.

Analyze

Behavioral insight & analytics

Bring us your existing video, voice, or trial data. Our multimodal models surface vocal, facial, and linguistic biomarkers you couldn't see in PRO data alone.

Time-to-value in weeks, on data you already own.

Co-Develop · End-to-End

Digital models & endpoints

Start from a clinical hypothesis. We build the digital endpoint, the screener, or the response model end-to-end — from study design through peer review.

The path we walked with TDScreen and Check on Mom.

Three ways to start.

Many partners start at one of three points and grow from there. The endpoint roadmap does not require starting at zero.

Path A

Bring your dataset

You have a behavioral dataset: video, audio, or rated session data. We run it through our validated models and surface what's there.

Weeks

Path B

We capture, you analyze

Use our cart and web platform as your capture layer. We deliver a clean, structured dataset. Your team handles downstream analysis, or we collaborate.

One study

Path C

Co-develop a novel endpoint

End-to-end. Study design, capture, model development, peer-reviewed validation — with your team.

Trial-arm aligned

Trials and observation

Each product, purpose-built.

The same capture stack, delivered as two cart solutions plus a centralized streaming layer. Each built for the level of observation your protocol needs.

In the clinic · On the cart

In the clinic · On the cart

On the patient's device · Anywhere

RoomView

Ambient room & patient observation

Broad, continuous observation of the full room and the patient.

Videra algorithms run on captured video, voice, and movement signal — triggering alerts on abnormalities, acute findings, and protocol-defined events.

  • Cart built for full-room and patient capture
  • AI analysis on the captured signal
  • Real-time alerts on acute findings

FidelityView

High-fidelity encounter monitoring

Multi-view cameras, hi-fi audio, close-contact patient-provider observation.

Purpose-built to monitor protocol adherence remotely and protect the fidelity of the trial. The defensible record FDA monitors and regulatory teams expect.

  • Cart built for close-contact capture
  • Multi-view cameras + hi-fi audio
  • Remote protocol-adherence monitoring

RemoteView

Patient-led assessment, anywhere

Asynchronous video, audio, and structured questions on the patient's own device.

No app, no login. The same multimodal models that run in clinic, delivered outside the clinic — for trials and commercial use cases.

  • On the patient's own device
  • No app, no login
  • Trials and commercial

In the room · Centrally monitored

LiveView

Centralized live observation, multi-room

Stream Videra carts from one or many rooms to a single central observation point, scaling oversight across trial and commercial settings — in clinic and at commercial launch. The same stack you run in trials extends directly into post-market.

What it unlocks for sponsors

More signal. Less variance. Defensible data.

What our partners actually get from running Videra inside their trial — the asset value extends well past the database lock.

I.

Standardized behavioral datasets across sites and visits.

II.

Remote oversight and rater audit, without flying monitors to every site.

III.

Real-time safety escalation, with alerts triggered on observed signal.

IV.

Endpoint readiness — digital endpoints built into the trial, not bolted on after.

V.

Better completion and retention through engaging, low-burden capture.

VI.

A behavioral asset that outlasts the trial, ready for Phase 4 and commercial.

Outside of clinic · On a patient's own device

A web-based assessment your patients actually finish.

Patients receive a text, tap a link, and complete a validated video session on their own device. No app, no login. The same multimodal capture and AI signal extraction runs on a phone as it does on the cart — extending the observation suite beyond the clinic.

REMS

Risk & safety monitoring

Scheduled check-ins with built-in alert escalation for desired analytics.

Fidelity

Protocol fidelity

Standardized prompts and AI-scored responses across sites, so monitors and statisticians get comparable data.

Remote

Remote observation

Continuous visibility between in-clinic visits, without adding site burden or hardware.

Adherence

Engagement & completion

Video-based prompts hold attention better than survey instruments. Completion rates show it.

Spotlight · In-market AI screeners

Pharma-sponsored AI screeners, already in market.

We co-develop and commercialize disease-specific screeners with pharma partners that care most about identifying a given condition.

Live · In Market

TDSCREEN.AI · Tardive Dyskinesia

AI-powered TD screening

A short, video-based assessment that quantifies involuntary movements associated with TD. Device-agnostic, remote-capable, reducing reliance on subjective rating.

  • Early & objective detection
  • Scalable, remote, device-agnostic
  • Geographic, demographic, prevalence RWE
  • Supports post-market & HEOR strategies
tdscreen.ai →
Live · In Market

CHECKONMOM.AI · Perinatal & Postpartum

AI-powered PPD screening

A consumer-friendly video assessment that surfaces postpartum risk earlier than standard EPDS administration. Routes to care with rich behavioral signal.

  • Multi-touch perinatal monitoring
  • Routes to provider with rich signal
  • Built for advocacy + commercial channels
  • Pharma-sponsored deployment model
checkonmom.ai →

Trust & compliance

Built for regulated work.

Videra runs in clinical trials, hospital systems, and pharma-sponsored programs. Compliance and audit trails are foundational, not bolted on.

  • FDA-registered platform as a SaMD
  • HIPAA-compliant infrastructure and processes
  • SOC 2 Type II certified
  • 21 CFR Part 11 ready for regulated trials
  • Auditable data flows, retention, and access controls
  • End-to-end encrypted pipeline
HIPAA SOC 2 Type II 21 CFR Part 11 FDA SaMD

Selected publications

01
Detecting Tardive Dyskinesia Using Video-Based Intelligence
Journal of Clinical Psychiatry · May 2025
02
Multimodal Machine Learning for Video-Based Single Question MHQ
NPJ Digital Medicine · December 2025
03
Evaluation of Automated Video-Based Model for Detecting TD using the CTI
JMIR · May 2026

Let's keep talking

A 30-minute conversation, tailored to your program.

Bring us a question and we'll walk you through what behavioral evidence looks like inside your specific trial or commercial program — from study design to digital endpoint to real-world deployment.

Book a walkthrough →

Your Videra contact

Ryan Roberts
Videra Health · Life Sciences
ryan@viderahealth.com viderahealth.com →